HC Wainwright reissued their buy rating on shares of OvaScience Inc. (NASDAQ:OVAS) in a report published on Friday, May 12th. HC Wainwright currently has a $15.00 target price on the biotechnology company’s stock.
OVAS has been the topic of a number of other reports. Zacks Investment Research upgraded OvaScience from a hold rating to a buy rating and set a $1.75 price target on the stock in a research note on Wednesday, February 8th. Credit Suisse Group restated an underperform rating and issued a $1.00 price target on shares of OvaScience in a research note on Tuesday, April 18th. Finally, Oppenheimer Holdings, Inc. restated a hold rating on shares of OvaScience in a research note on Wednesday, March 22nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $6.38.
Shares of OvaScience (NASDAQ:OVAS) traded up 0.74% during trading on Friday, hitting $1.36. The stock had a trading volume of 217,862 shares. The stock has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.70. OvaScience has a 12 month low of $1.25 and a 12 month high of $8.98. The company’s market cap is $48.50 million.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.08. OvaScience had a negative return on equity of 61.67% and a negative net margin of 13,227.72%. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.12 million. During the same period last year, the firm earned ($0.80) earnings per share. OvaScience’s quarterly revenue was down 56.8% on a year-over-year basis. Equities analysts expect that OvaScience will post ($1.58) EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of OVAS. Teachers Advisors LLC boosted its position in shares of OvaScience by 53.0% in the fourth quarter. Teachers Advisors LLC now owns 68,249 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 23,643 shares during the period. UBS Asset Management Americas Inc. bought a new position in shares of OvaScience during the first quarter valued at about $107,000. Northern Capital Management LLC boosted its position in shares of OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 44,175 shares during the period. Morgan Stanley boosted its position in shares of OvaScience by 2.8% in the first quarter. Morgan Stanley now owns 160,363 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 4,394 shares during the period. Finally, KCG Holdings Inc. bought a new position in shares of OvaScience during the first quarter valued at about $375,000. Hedge funds and other institutional investors own 63.66% of the company’s stock.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
What are top analysts saying about OvaScience Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OvaScience Inc. and related companies.